Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir

Virology Journal

Gaston Picchio²  Donghan Luo²  Maria Beumont¹  Inge Dierynck¹  Anne Ghys¹  Sandra De Meyer¹ 

[1] Janssen Infectious Diseases BVBA, Turnhoutseweg 30, B2340 Antwerpen, Beerse, Belgium;Janssen Research and Development, Titusville, NJ, USA

关键词: Viral kinetics;    Telaprevir;    Resistance;    Mutation;    HCV;    Genotype 4;   

Others  :  804219
DOI  :  10.1186/1743-422X-11-93

 received in 2013-12-17, accepted in 2014-05-02,  发布年份 2014

【 摘 要 】

Background

Study C210 was a Phase IIa, exploratory trial to assess the activity of telaprevir on hepatitis C virus (HCV) early viral kinetics in treatment-naïve patients infected with genotype 4 (G4) HCV.

Methods

Patients were randomized to receive peginterferon and ribavirin alone, telaprevir monotherapy (T arm), or telaprevir in combination with peginterferon/ribavirin (TPR arm) for 15 days, followed by a 46- or 48-week standard treatment phase. The current analysis aimed to characterize the genotype and phenotype of HCV G4 variants emerging during telaprevir treatment.

Results

Five of the 8 (62.5%) patients in the telaprevir (T) arm had viral breakthrough (vBT) during the investigational treatment phase (between baseline and Day 15), compared to no patients in the TPR arm. HCV G4 viral variants with a T54A/T mutation were detected in two of these patients, as well as two other patients with detectable HCV RNA at the end of telaprevir treatment. Emergence of the T54A/T mutation was associated with a 2- to 4-fold decreased susceptibility to telaprevir. All patients with vBT during the investigational treatment phase or with a T54A/T mutation achieved undetectable HCV RNA 12 or 24 weeks after end of treatment with subsequent peginterferon/ribavirin treatment.

Conclusions

In this analysis in G4 HCV-infected patients, more patients in the telaprevir monotherapy arm experienced vBT with resistant variants compared to none with telaprevir combination therapy. The most commonly selected mutation T54A in telaprevir-treated G4 HCV patients was previously described in the context of G1 infection.

Trial registration

The trial was registered with ClinicalTrials.gov (NCT00580801).

【 授权许可】

   
2014 De Meyer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]WHO: Global surveillance and control of hepatitis c. report of a who consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999, 6:35-47.
• [2]Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
• [3]Sy T, Jamal MM: Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3:41-46.
• [4]Kamal SM, Nasser IA: Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology 2008, 47:1371-1383.
• [5]Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K: Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco California. BMC Infect Dis 2011, 11:208. BioMed Central Full Text
• [6]Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD: Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J Clin Microbiol 2011, 49:3040-3043.
• [7]INCIVEK® (telaprevir) US FDA Prescribing InformationAvailable from: http://pi.vrtx.com/files/uspi_telaprevir.pdf webcite. Accessed May 7 2014
• [8]INCIVO® (telaprevir) EU Summary of Product CharacteristicsAvailable from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf webcite. Accessed May 7 2014
• [9]Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M: REALIZE study team: telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
• [10]Sarrazin C, Zeuzem S: Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
• [11]Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
• [12]Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G: Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012, 7:e34372.
• [13]Lin C, Hanzelka B, Muh U, Kovari L, Bartels DJ, Tigges AM, Miller J, Rao BG, Kwong AD: Telaprevir (VX-950) is a potent inhibitor of HCV NS3-4A proteases derived from genotype non-1 HCV infected patients. J Hepatol 2007, 46(Suppl S1):S8.
• [14]Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatology 2011, 54:1433-1444.
• [15]Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F: Observational VHC4 Study Group: epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007, 14:460-467.
• [16]Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M: Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013, 208:1000-1007.
• [17]Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S: Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007, 46:640-648.
• [18]Kieffer T, Bartels D, Sullivan J, Adiwijaya BS, Zhang EZ, Tigges A, Dorrian J, Spanks J, De Meyer W, Picchio G, Adda N, Kwong AD: Clinical virology results from telaprevir Phase 3 study ADVANCE. [61st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 29–November 2, 2010. Abstract LB-11]
• [19]De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G: Analysis of genotype 2 and 3 HCV variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat 2013, 20:395-403.
• [20]Zeuzem S, Sulkowski M, Zoulim F, Sherman KE, Alberti A, Wei LJ, van Baelen B, Sullivan J, Kieffer TL, De Meyer S, Picchio G, Tomaka F, Graham CS8, McHutchison JG: Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 2010, 52(Suppl):436A.
• [21]Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA: Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006, 70:28-38.
• [22]Lin K, Kwong AD, Lin C: Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004, 48:4784-4792.